Novel hormone essential for heart development discovered

December 6, 2013, Agency for Science, Technology and Research (A*STAR), Singapore

Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases. The hormone - which they have chosen to name ELABELA - is only 32 amino-acids long, making it amongst the tiniest proteins made by the human body.

The team led by Dr Bruno Reversade carried out experiments to determine ELABELA's function, since its existence was hitherto unsuspected. Using zebrafish designed to specifically lack this hormone, they uncovered that ELABELA is indispensable for heart formation. Zebrafish embryos without this gene had rudimentary or no heart at all (see Figure 1). Their results were published in the 5 December 2013 online issue of Developmental Cell.

Deficiencies in hormones are the cause of many diseases, such as the loss of insulin or insulin resistance, that results in diabetes, and irregularities in appetite and satiety hormones that can cause obesity. Hormones are known to control functions such as sleep, appetite and fertility. However, this is the first time that scientists have revealed the existence of a conserved[1] hormone playing such an early role during embryogenesis, effectively orchestrating the development of an entire organ.

The team also found that ELABELA uses a receptor previously believed to be specific to APELIN, a blood-pressure controlling hormone. This receptor called APJ or Apelin Receptor has dual functions - it first conveys signals from ELABELA and then from APELIN. Mutations in the Apelin Receptor also prevent the heart from forming. Zebrafish bereft of the Apelin Receptor are referred to as the Grinch, in reference to the cold and heartless cartoon character created by Dr. Seuss in 1957.

ELABELA has also been found to be expressed in human embryonic stem cells[2], indicating that it might have other functions beyond its role in cardiovascular development.

The team's findings hold great promise for the potential use of ELABELA as a therapeutic molecule for cardiovascular disease to be used in cardiac repair and control of hypertension. As some people might have a harmful copy of the ELABELA gene in their genetic make-up, sequencing and screening for this particular gene in the general population might also help to detect predisposition to anomalies before the disease progresses.

Dr Bruno Reversade said, "The human genome has been sequenced over a decade ago. That we can still find anonymous hormones charms me. There are a still a few more to discover…but not for long."

Prof Birgitte Lane, Executive Director of IMB, said, "This discovery shows great promise for the development of targeted therapies for and in the future. It is an excellent example of how basic research can lead to surprising and unexpected findings that may change and refine medical practice."

Prof Hong Wan Jin, Executive Director of IMCB, said, "I am very pleased with Bruno's achievement as it reflects the synergy of collaboration and joint efforts among various research institutes in Singapore."

Explore further: Discovery of new heart failure trigger could change the way cardiovascular drugs are made

More information: "ELABELA: A Hormone Essential for Heart Development Signals via the Apelin Receptor." Serene C. Chng, Lena Ho, Jing Tian, Bruno Reversade. Developmental Cell, 5 December 2013. DOI: 10.1016/j.devcel.2013.11.002

Related Stories

Discovery of new heart failure trigger could change the way cardiovascular drugs are made

July 18, 2012
In their quest to treat cardiovascular disease, researchers and pharmaceutical companies have long been interested in developing new medicines that activate a heart protein called APJ. But researchers at Sanford-Burnham Medical ...

New class of drug targets heart disease

September 17, 2013
(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Disruption of cellular signaling identified in pulmonary arterial hypertension

December 27, 2012
(Medical Xpress)—Impairment of a key signaling cascade in the pulmonary blood vessels plays an important role in pulmonary arterial hypertension, a Yale study has found. The study appears in the advance online publication ...

First gene detected for most common form of mitral valve prolapse

October 24, 2013
Research on the DNA of a large multi-generational family has provided a genetic clue that enabled scientists to pinpoint a gene that plays a role in mitral valve prolapse (MVP), a common cardiac disease that is a leading ...

Recommended for you

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.